Meksidol forte 250 Table n / 250mg film about 40 pc

Description

Composition
Active substance:
emoxypine in terms of 100% substance – 250.0 mg.
Excipients:
Lactose monohydrate, povidone K-30, magnesium stearate.
Film coating: Opadry II pink 33G240018 (hypromellose, titanium dioxide, lactose monohydrate, macrogol 4000, triacetin, iron oxide red dye, iron oxide yellow dye).
Description:
round biconvex tablets, film-coated light pink color. On the cross-section of the core is almost white.
Product form:
tablets, film-coated, 250 mg. 10 tablets, film-coated, in blisters of PVC film and aluminum foil. 4 blisters together with instructions for use in a cardboard pack.
Contraindications
acute disorders of liver and kidney function, heightened individual sensitivity to the drug. Due to insufficient knowledge of the drug – the children’s age, pregnancy, breastfeeding.
Dosage
250 mg
Indications
– the effects of stroke, including after transient ischemic attacks, in phase subcompensation as prevention courses;
– mild traumatic brain injury, the effects of traumatic brain injury;
– encephalopathies of various origins (discirkulatornaya, dysmetabolic, posttraumatic mixed);
– autonomic dystonia syndrome;
– mild cognitive disorders of atherosclerotic;
– Anxiety disorders in neurotic and neurosis-like states;
– coronary heart disease in the complex therapy;
– relief of abstinence syndrome in alcoholism with prevalence of neurosis and vegetative-vascular disorders, postabstinentnom disorder;
– states after acute intoxication antipsychotics;
– asthenic conditions, as well as for the prevention of systemic diseases under the influence of extreme factors and loads;
– exposure to extreme (stress) factors.
Interaction with other drugs
MEXIDOL® FORTE 250 is compatible with all drugs used for the treatment of systemic diseases.
It increases the effects of benzodiazepine drugs, antidepressants, anxiolytics, antiepileptics (carbamazepine) and antiparkinsonian agents (levodopa) nitrate. Reduces toxic action of ethanol.
Overdose
Symptoms: drowsiness, insomnia.
Treatment: Due to the low toxicity overdose is unlikely. Treatment usually is not required – the symptoms disappear on their own within a day. When expressed manifestations carried supportive and symptomatic treatment.
pharmachologic effect
Pharmacological group:
anti-oxidant agent.
Pharmacodynamics:
MEXIDOL® FORTE 250 is an inhibitor of free radical processes, membrane protectors having antihypoxic, stress-protective, neuroprotective, antiepileptic and anxiolytic action. It refers to a class of 3-hydroxypyridine.
The mechanism of action MEXIDOL® FORTE 250 due to its antioxidant, antihypoxic and membrane action. It inhibits lipid peroxidation, superoxide dismutase activity increases and increases the ratio of lipid-protein improves the structure and function of cell membranes. The drug modulates the activity of membrane-associated enzymes (calcium-independent phosphodiesterase, adenylate cyclase, acetylcholinesterase) receptor complexes (benzodiazepine, gamma-aminobutyric acid (GABA), acetylcholine), which increases their binding ability with ligands contributes to maintaining structural and functional organization of biological membranes, transport of neurotransmitters and improve synaptic transmission. MEXIDOL® FORTE 250 increases the concentration of dopamine in the brain. Causes increased activation of compensatory aerobic glycolysis and decreased inhibition of oxidative processes in the Krebs cycle under hypoxic conditions with increasing content of adenosine triphosphate (ATP) and creatine phosphate, energosinteziruyuschih activation of mitochondrial function.
Increases resistance to the impact of various harmful factors in pathological states (hypoxia and ischemia, cerebrovascular disease, intoxication with ethanol and antipsychotics).
In the context of the critical reduction in coronary blood flow helps to preserve the structural and functional organization of the cardiomyocyte membrane, stimulates the activity of membrane enzymes – phosphodiesterase, adenylate cyclase, acetylcholinesterase. Supports evolving during acute ischemia activation and promotes aerobic glycolysis in hypoxia recovery mitochondrial redox processes, increases the synthesis of ATP and creatine phosphate. It ensures the integrity of morphological structures and physiological functions of the ischemic myocardium. Improves the clinical course of myocardial infarction, improves the efficiency of the therapy reduces the incidence of arrhythmias and conduction disorders intracardiac. Normalize metabolic processes in the ischemic myocardium, increases antianginal nitrate activity, improves blood rheology, reduces the effects of reperfusion syndrome in acute coronary insufficiency.
Decreases enzymatic toxemia and the endogenous toxicity in acute pancreatitis.
Improves cerebral metabolism and blood circulation, improve microcirculation and blood rheology, reduce platelet aggregation. Stabilizes the membrane structure of blood cells (erythrocytes and platelets), reducing the likelihood of hemolysis. It has hypolipidemic effect, reduces total cholesterol and low density lipoproteins.
Anti-stress effect is the normalization of post-stress behavior, somatovegetativnyh violations, restoration of the sleep-wake cycles, broken processes of learning and memory, and reducing degenerative morphological changes in different brain structures.
MEXIDOL® FORTE 250 has a pronounced effect when antitoxic withdrawal syndrome. It eliminates neurological and neurotoxic manifestations of acute alcohol intoxication, restores behavioral, autonomic functions, and is able to remove the cognitive impairment caused by prolonged use of ethanol and its abolition. Under the influence of the action of the drug is enhanced anxiolytic, antipsychotic, antidepressant, hypnotic and anticonvulsant drugs, thus reducing their dose and reduce side effects.
MEXIDOL® FORTE 250 improves the functional state of ischemic myocardium. In the context of coronary insufficiency increases collateral blood flow to ischemic myocardium, helps to preserve the integrity of cardiomyocytes and maintaining their functional activity. Effectively restores myocardial contractility with reversible cardiac dysfunction.
Pharmacokinetics:
Quickly absorbed by ingestion. The maximum concentration (Cmax) at doses of 400-500 mg of 3.5-4.0 g / ml. Rapidly distributed to organs and tissues. The mean retention time (MRT) of the drug in the body when taken orally – 4.9-5.2 hours. It is metabolized in the liver by glyukuronkonyugirovaniya. 5 metabolites have been identified: 3-hydroxypyridine phosphate produced in the liver, with the participation of alkaline phosphatase decomposes to phosphoric acid, and 3-hydroxypyridin; 2nd metabolite – a pharmacologically active, is formed in large amounts and found in urine for 1-2 days. after administration; Third – is displayed in large amounts in the urine; 4 th and 5 th – glyukuronkonyugaty. The half-life (T1 / 2) ingestion – 2.0-2.6 hours. Rapidly excreted in the urine primarily as metabolites in small quantities – unchanged. The most intense output in the first 4 hours after ingestion. Indicators excretion in the urine unchanged drug and metabolites have individual variability.
Pregnancy and breast-feeding
drug MEXIDOL® 250 FORTE is contraindicated in pregnancy and during breastfeeding.
Conditions of supply of pharmacies
prescription.
side effects
possible occurrence of individual adverse reactions or dyspeptic dyspeptic nature of allergic reactions.
special instructions
Effect of the drug on the ability to drive or operate machinery: during ingestion caution when working, which requires quickness psychophysical reactions (management of vehicles, machinery, etc.).
Storage conditions
stored in the dark place at a temperature not higher than 25 ° C. Keep out of the reach of children.
Dosing and Administration
Inside of 250 mg 3 times a day.
Starting dose – 250 mg (1 tablet) 1-2 times a day with gradual increase to a therapeutic effect. The maximum daily dose – 750 mg (3 tablets).
The duration of the treatment – 2-6 weeks; for the relief of alcohol withdrawal – 5-7 days. Duration of therapy in patients with coronary heart disease, at least 1,5-2 months.
Repeated courses (on doctor’s advice), preferably carried out in the spring and autumn periods.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist